Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMX3009
- Development stage
- Phase 2
- Lead developer
- Arromax Pharmatech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMX3009 is an orally administered small molecule inhibitor targeting both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ERBB2). It is being developed primarily for the treatment of cancers with rare EGFR mutations, such as locally advanced or metastatic non-small cell lung cancer (NSCLC), and has also been studied in HER2-positive advanced solid tumors. The drug acts as a dual EGFR/HER2 antagonist, aiming to inhibit tumor cell proliferation driven by these pathways. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and efficacy in these patient populations[1][2][3].
- Other names
- AMX-3009 MaleateAMX3009 MaleateAMX 3009 Maleate
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on AMX3009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMX3009.